instead, the multisystem pathologic processes that are associated with this condition have long been well established as drivers of its clinical presentation and outcomes.470 One could argue that the success of sodium-glucose cotransporter 2 (SGLT2) inhibitors, and now of GLP-1RAs, suggests that metabolic abnormalities play an important role in driving HFpEF.470 SGLT2 inhibition is also known to benefit patients with heart failure and a reduced ejection fraction.471 The mechanisms by which SGLT2 inhibitors treat heart failure include lowering blood glucose levels by inhibiting the SGLT2 protein in the renal tubules and reducing glucose reabsorption in the tubules.472 Promoting the urinary excretion of sodium and water reduces fluid retention and hypervolaemia, thereby reducing the load on the heart.473 It also improves myocardial energy metabolism, increases fatty acid oxidation in the myocardium, and improves myocardial energy supply.474 Moreover, these agents reduce the risks of myocardial inflammation and fibrosis and improve cardiac structure and function.475 By the way, a clinical study published in Nature Metabolism detailed the effects of semaglutide and dapagliflozin (an SGLT2 inhibitor) on blood sugar control in patients with T2DM of different pathophysiological types.476 It was found that semaglutide performed better than dapagliflozin in reducing HbA1c levels.476 The study results suggest that semaglutide may be a more suitable choice for patients with severe insulin deficiency, while dapagliflozin might be effective for a broader range of patients with metabolic abnormalities.476 If SGLT2 inhibitors and GLP-1RAs are effective in patients with heart failure (regardless of whether the ejection fraction is reduced or preserved), the commonalities between the two types of heart failure may be greater than is often thought

The SELECT trial, which followed over 17,000 participants, showed that 16.6% of semaglutide-treated patients discontinued due to adverse events compared to 8.2% on placebo
Gray market products exist in an in-between space, since theyre not exactly illegal, but are obtained through channels that lack proper authorization for personal use, says Dr
Vitamin B-complex synergy studies in controlled laboratory systems
Of note, the ADA supports a multifactorial approach to reducing cardiovascular risk and diabetes-related complications emphasising the importance of managing glycaemic control, blood pressure, and lipid levels, alongside incorporating therapies with proven cardiovascular and kidney benefits
Afecta a una proporcin sustancial de la poblacin y a todos los grupos de edad